Lipocine posts third-quarter results and advances postpartum depression trial
+2 new sources since this summary was written
On November 5, Lipocine reported third-quarter 2026 revenue of $2.3 million and a quarterly net loss of $0.7 million, or ($0.08) per diluted share. The company said its BLOOM outpatient Phase 3 trial for BRLIZIO in postpartum depression began in September and is intended to support a possible NDA filing. Lipocine also disclosed Canadian approval for TLANDO and further plans for its other neuroactive-steroid programs.
Why it matters
The update gives investors current liquidity, operating results and development milestones. BRLIZIO's potential NDA path remains dependent on a successful, well-controlled Phase 3 trial, while TLANDO's Canadian launch is planned for early 2027.
Key facts
- 1The BLOOM study is expected to enroll approximately 120 participants with postpartum depression. prnewswire.com
- 2Lipocine held $21.5 million in unrestricted cash, cash equivalents and marketable investment securities as of September 30, 2026. prnewswire.com
- 3Health Canada approved TLANDO capsules in September 2026 for testosterone replacement therapy in adult males with male hypogonadism. prnewswire.com
- 4FDA feedback indicated that one successful, well-controlled Phase 3 trial was still needed for the potential 505(b)(2) NDA submission. prnewswire.com
- 5For the nine months ended September 30, 2026, Lipocine recorded a net loss of $7.0 million, or ($0.90) per diluted share. sec.gov
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.